Spero Therapeutics, Inc. (SPRO) Financial Statements (2024 and earlier)

Company Profile

Business Address 675 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments77,69096,254109,10750,44645,401121,966
Cash and cash equivalents77,69096,254109,10750,44645,40172,111
Short-term investments      49,855
Other undisclosed current assets10,6595,4084,4632,4416,55310,738
Total current assets:88,349101,662113,57052,88751,954132,704
Noncurrent Assets
Operating lease, right-of-use asset4,6484,8885,1245,3565,5846,309
Property, plant and equipment148256368494623888
Other noncurrent assets5,7405,7405,7405,7395,4675,929
Total noncurrent assets:10,53610,88411,23211,58911,67413,126
TOTAL ASSETS:98,885112,546124,80264,47663,628145,830
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,2017,1857,31913,3497,8069,693
Employee-related liabilities4,8602,2072,397
Accounts payable1,3105836172,5821,7114,780
Accrued liabilities2,8916,6026,7025,9073,8882,516
Deferred revenue8,70911,84510,3693,7262,3642,093
Derivative instruments and hedges, liabilities    141115995
Other undisclosed current liabilities4,4143,9573,961(991)3,94456,418
Total current liabilities:17,32422,98721,64916,22514,22969,199
Noncurrent Liabilities
Long-term debt and lease obligation7285965,3255,5905,854
Long-term debt, excluding current maturities728596107117128
Liabilities, other than long-term debt26,70724,63527,123   
Deferred revenue22,30019,95022,166   
Operating lease, liability4,4074,6854,9575,2185,4735,726
Other undisclosed noncurrent liabilities    5,2242,4132,578
Total noncurrent liabilities:26,77924,72027,21915,76713,47614,158
Total liabilities:44,10347,70748,86831,99227,70583,357
Equity
Equity, attributable to parent54,78264,83975,93432,48435,92362,473
Preferred stock     23
Common stock535352433533
Additional paid in capital493,787491,930489,760473,090464,860462,735
Accumulated other comprehensive loss      (6)
Accumulated deficit(439,058)(427,144)(413,878)(440,649)(428,974)(400,292)
Total equity:54,78264,83975,93432,48435,92362,473
TOTAL LIABILITIES AND EQUITY:98,885112,546124,80264,47663,628145,830

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues2,7162,06947,4412,0061,9932,069
Gross profit:2,7162,06947,4412,0061,9932,069
Operating expenses(15,606)(16,296)(21,517)(13,840)(28,073)(32,276)
Operating income (loss):(12,890)(14,227)25,924(11,834)(26,080)(30,207)
Nonoperating income (expense)976961847159(2,602)(2,622)
Investment income, nonoperating98296371520811172
Other undisclosed loss from continuing operations before equity method investments, income taxes   (3,581)   
Income (loss) from continuing operations before equity method investments, income taxes:(11,914)(13,266)23,190(11,675)(28,682)(32,829)
Other undisclosed income from continuing operations before income taxes   3,581   
Income (loss) from continuing operations before income taxes:(11,914)(13,266)26,771(11,675)(28,682)(32,829)
Income tax expense      
Income (loss) from continuing operations:(11,914)(13,266)26,771(11,675)(28,682)(32,829)
Loss before gain (loss) on sale of properties:(11,675)(28,682)(32,829)
Net income (loss):(11,914)(13,266)26,771(11,675)(28,682)(32,829)
Other undisclosed net income (loss) attributable to parent14(34)14(25)(18)29
Net income (loss) attributable to parent:(11,900)(13,300)26,785(11,700)(28,700)(32,800)
Other undisclosed net income (loss) available to common stockholders, basic(14)3492,8162518(29)
Net income (loss) available to common stockholders, diluted:(11,914)(13,266)119,601(11,675)(28,682)(32,829)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(11,914)(13,266)26,771(11,675)(28,682)(32,829)
Comprehensive income (loss):(11,914)(13,266)26,771(11,675)(28,682)(32,829)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent     6(4)
Comprehensive income (loss), net of tax, attributable to parent:(11,914)(13,266)26,771(11,675)(28,676)(32,833)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: